PERBANDINGAN KADAR HIGH SENSITIVITY C-REACTIVE PROTEIN (hs-CRP) METODE Fluoroescence Immunoassay (FIA) ANTARA SAMPEL SERUM DAN PLASMA EDTA PADA PENDERITA DIABETES MELITUS
DOI:
https://doi.org/10.51878/healthy.v5i4.13729Keywords:
High-Sensitivity C-Reactive Protein,Serum,Plasma EDTAAbstract
Diabetes mellitus is a chronic metabolic disorder associated with increased inflammatory activity and contributes to the development of cardiovascular complications. High-sensitivity C-reactive protein (hs-CRP) serves as an inflammatory marker to evaluate low-grade systemic inflammation. Accurate specimen selection is crucial for analytical validity. This study aims to compare hs-CRP levels measured by Fluorescence Immunoassay (FIA) between serum and EDTA plasma specimens in patients with diabetes mellitus. An observational comparative study with a cross-sectional design was conducted using 20 paired serum and EDTA plasma samples from diabetes mellitus patients at Haji General Hospital, East Java Province, in March 2026. hs-CRP levels were measured using the FIA method. The mean hs-CRP concentration in serum was ( ) and in EDTA plasma was ( ). The Wilcoxon Signed Rank Test yielded a of 0.463 ( ), indicating no statistically significant difference between serum and EDTA plasma hs-CRP levels. In conclusion, serum and EDTA plasma demonstrate analytical equivalence for hs-CRP measurement using the FIA method, allowing EDTA plasma to serve as a valid alternative specimen in routine laboratory practice.
ABSTRAK
Diabetes melitus merupakan gangguan metabolisme kronis yang berkaitan dengan peningkatan aktivitas inflamasi dan berkontribusi terhadap perkembangan komplikasi kardiovaskular. High-sensitivity C-reactive protein (hs-CRP) digunakan sebagai penanda inflamasi untuk menganalisis proses peradangan kronis tingkat rendah (low-grade inflammation). Ketepatan pemilihan spesimen laboratorium sangat memengaruhi validitas analitik. Penelitian ini bertujuan untuk membandingkan kadar hs-CRP metode Fluorescence Immunoassay (FIA) antara spesimen serum dan plasma EDTA pada penderita diabetes melitus. Penelitian observasional komparatif dengan desain cross-sectional ini dilakukan terhadap 20 pasang spesimen serum dan plasma EDTA dari pasien diabetes melitus di RSUD Haji Provinsi Jawa Timur pada Maret 2026. Kadar hs-CRP diukur menggunakan metode FIA. Hasil penelitian menunjukkan rerata kadar hs-CRP serum sebesar ( ) dan plasma EDTA sebesar ( ). Hasil uji Wilcoxon Signed Rank Test menghasilkan nilai ( ), yang menunjukkan tidak terdapat perbedaan yang bermakna secara statistik antara kadar hs-CRP pada spesimen serum dan plasma EDTA. Kesimpulannya, serum dan plasma EDTA memiliki kesepadanan analitik dalam pemeriksaan hs-CRP metode FIA, sehingga plasma EDTA dapat digunakan sebagai spesimen alternatif yang valid dalam kondisi darurat laboratorium.
References
Ballard, Z. S., Joung, H., Goncharov, A., Liang, J., Nugroho, K., Carlo, D. D., Garner, O. B., & Özcan, A. (2020). Deep learning-enabled point-of-care sensing using multiplexed paper-based sensors. npj Digital Medicine, 3(1), Article 66. https://doi.org/10.1038/s41746-020-0274-y
Borges, J. Y. V. (2024). Precision medicine in cardiology: An evolving understanding of biomarkers in coronary artery disease prevention a 10-year thematic review. medRxiv. https://doi.org/10.1101/2024.07.01.24309804
Brindle, E., Fujita, M., Shofer, J., & O'Connor, K. A. (2010). Serum, plasma, and dried blood spot high-sensitivity C-reactive protein assay validation for population research. Bioanalysis, 2(2), 269–280. https://doi.org/10.4155/bio.09.182
Caruso, B., Bovo, C., & Guidi, G. C. (2020). Causes of preanalytical interferences on laboratory immunoassays - A critical review. EJIFCC, 31(1), 70–84. https://doi.org/10.1234/ejifcc.v31i1.2020
Darwin, B. (2022). Perbandingan kadar C-Reactive Protein (CRP) pada sampel serum dan plasma lithium heparin. Masker Medika, 10(2), 672–677. https://doi.org/10.52523/maskermedika.v10i2.488
Farmaki, P., Damaskos, C., Garmpis, N., Garmpi, A., Savvanis, S., & Diamantis, E. (2020). Complications of the type 2 diabetes mellitus. Current Cardiology Reviews, 16(4), 249–251. https://doi.org/10.2174/1573403X1604201229115531
Febrianto, D., Soelistijo, S. A., & Tjempakasari, A. (2023). Correlation between serum high-sensitivity C-reactive protein level and severity of albuminuria measured by urine albumin-to-creatinine ratio in type 2 diabetic patients. Current Internal Medicine Research and Practice Surabaya Journal, 4(2), 55–62. https://doi.org/10.20473/cimrj.v4i2.49152
Hedayati, M. (2020). The impact of pre-analytical variations on biochemical analytes stability: A systematic review. Journal of Clinical Laboratory Analysis, 34(12), Article e23551. https://doi.org/10.1002/jcla.23551
Helniasari, Nurhidayanti, & Darwin, B. (2022). Perbedaan kadar C-Reaktive Protein (CRP) pada sampel serum dan plasma K3EDTA dengan metode imunoturbidimetri. The Journal of Muhammadiyah Medical Laboratory Technologist, 5(2), 112–120. https://doi.org/10.30651/jmlt.v5i2.13350
Hoogeveen, R. M., Pereira, J., Nurmohamed, N. S., Zampoleri, V., Bom, M. J., Baragetti, A., Boekholdt, S. M., Knaapen, P., Khaw, K., Wareham, N. J., Groen, A. K., Catapano, A. L., Köenig, W., Levin, E., & Stroes, E. S. G. (2020). Improved cardiovascular risk prediction using targeted plasma proteomics in primary prevention. European Heart Journal, 41(41), 3998–4007. https://doi.org/10.1093/eurheartj/ehaa648
Katharina, E., Nabu, Y., Herawati, S., & Mulyantari, N. K. (2021). Perbandingan kadar Thyroid Stimulating Hormone (TSH) dan kadar Free T4 (FT4) antara metode Fluorescence Immunoassay (FIA) dan metode Electrochemiluminescence Immunoassay (ECLIA) di RSUP Sanglah, Bali, Indonesia. Intisari Sains Medis, 12(2), 613–616. https://doi.org/10.15562/ism.v12i2.1062
Kim, J. H., & Lim, J. S. (2022). The association between C-reactive protein, metabolic syndrome, and prediabetes in Korean children and adolescents. Annals of Pediatric Endocrinology & Metabolism, 27(4), 273–280. https://doi.org/10.6065/apem.2142226.113
Mach, F., Koskinas, K. C., van Lennep, J. E. R., Tokgözo?lu, L., Badimón, L., Baigent, C., Benn, M., Binder, C. J., Catapano, A. L., De Backer, G., Delgado, V., Fabin, N., Ference, B. A., Graham, I., Landmesser, U., Laufs, U., Mihaylova, B., Nordestgaard, B. G., Richter, D., & Sabatine, M. S. (2025). 2025 focused update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias. Atherosclerosis, 409, Article 120479. https://doi.org/10.1016/j.atherosclerosis.2025.120479
Mahadevaiah, D. D. (2025). Association between high-sensitivity C-reactive protein (hs-CRP) and cardiovascular risk in type 2 diabetics. European Journal of Cardiovascular Medicine, 5(6), 301–304. https://doi.org/10.5083/ejcm/25-06-57
Mouliou, D. S. (2023). C-reactive protein: Pathophysiology, diagnosis, false test results and a novel diagnostic algorithm for clinicians. Diseases, 11(4), Article 132. https://doi.org/10.3390/diseases11040132
Munabari, A. S. (2022). Pengaruh penggunaan spesimen serum dan plasma EDTA terhadap kadar total protein. Jurnal Pranata Biomedika, 1(2), 134–140. https://doi.org/10.24167/jpb.v1i2.5153
Neumann, F., de Lemos, J. A., Apple, F. S., & Leong, D. P. (2025). Cardiovascular biomarkers for risk stratification in primary prevention. European Heart Journal, 46(39), 3823–3843. https://doi.org/10.1093/eurheartj/ehaf517
Nordin, G., Samuelsson, I., Andersson, B., & Börjeson, J. (1996). C-reactive protein: The difference between quantitation in serum and EDTA plasma. Scandinavian Journal of Clinical and Laboratory Investigation, 56(2), 123–127. https://doi.org/10.3109/00365519609088598
Olson, M. E., Hornick, M. G., Stefanski, A., Albanna, H. R., Gjoni, A., Hall, G. D., Hart, P. C., Rajab, I. M., & Potempa, L. A. (2023). A biofunctional review of C-reactive protein (CRP) as a mediator of inflammatory and immune responses: Differentiating pentameric and modified CRP isoform effects. Frontiers in Immunology, 14, Article 1264383. https://doi.org/10.3389/fimmu.2023.1264383
Pellegrini, V., La Grotta, R., Carreras, F., Giuliani, A., Sabbatinelli, J., Olivieri, F., Berra, C. C., Ceriello, A., & Prattichizzo, F. (2024). Inflammatory trajectory of type 2 diabetes: Novel opportunities for early and late treatment. Cells, 13(19), Article 1662. https://doi.org/10.3390/cells13191662
Peres, F. F. (2026). Lessons in biostatistics: Sample size and power in clinical studies. Biochemia Medica, 36(1), Article 010101. https://doi.org/10.11613/BM.2026.010101
Rahayu, T. A. I. A. M. (2020). Perbedaan kadar ureum serum dan plasma lithium heparin. Jurnal Labora Medika, 4(2), 42–46. https://doi.org/10.26714/jlabmed.4.2.2020.42-46
Sharif, S., van der Graaf, Y., Cramer, M. J., Kappelle, L. J., de Borst, G. J., Visseren, F. L. J., Westerink, J., van Petersen, R., Dinther, B. G. F., Algra, A., Grobbee, D. E., Rutten, G. E. H. M., Leiner, T., & Nathoe, H. M. (2021). Low-grade inflammation as a risk factor for cardiovascular events and all-cause mortality in patients with type 2 diabetes. Cardiovascular Diabetology, 20(1), Article 220. https://doi.org/10.1186/s12933-021-01409-0
Shi, R., Feng, L., Xu, W., Ye, D., Luo, B., Ym, L., Cao, H., & Tang, L. (2023). Value of glycemic dispersion index in predicting major adverse cardiovascular events in diabetic patients with concomitant acute coronary syndrome. Research Square. https://doi.org/10.21203/rs.3.rs-3602905/v1
Singh, B., Goyal, A., & Patel, B. C. (2025). C-reactive protein: Clinical relevance and interpretation. StatPearls Publishing.
Stone, W. L., Basit, H., Zubair, M., & Burns, B. (2024). Pathology, inflammation. StatPearls Publishing.
Wang, Y., Duan, Y., Zhang, Y., Li, N., Hu, Y., Gu, L., Hou, Y., & Ma, Y. (2025). Alcohol consumption, high-sensitivity C-reactive protein, and estimated glomerular filtration rate: Tripartite predictors of 10-year cardiovascular risk progression in patients with type 2 diabetes mellitus after COVID-19. Frontiers in Endocrinology, 16, Article 1609144. https://doi.org/10.3389/fendo.2025.1609144
Weinberg-Sibony, R., Segev, O., Dor, S., & Raz, I. (2024). Overview of oxidative stress and inflammation in diabetes. Journal of Diabetes, 16(10), Article e70014. https://doi.org/10.1111/1753-0407.70014
Williams, S. A., Ostroff, R., Hinterberg, M., Coresh, J., Ballantyne, C. M., Matsushita, K., Mueller, C., Walter, J., Jonasson, C., Holman, R. R., Shah, S. H., Sattar, N., Taylor, R., Lean, M. E. J., Kato, S., Shimokawa, H., Sakata, Y., Nochioka, K., Parikh, C. R., … Ganz, P. (2022). A proteomic surrogate for cardiovascular outcomes that is sensitive to multiple mechanisms of change in risk. Science Translational Medicine, 14(639), Article eabj9625. https://doi.org/10.1126/scitranslmed.abj9625
